Endologix submits premarket approval application to FDA for Detour system

Endologix has announced the submission of a premarket approval (PMA) application requesting approval for the Detour system to the US Food and Drug Administration (FDA). The Detour system, which earned FDA Breakthrough Device Designation, is a unique therapy that allows the creation of a fully percutaneous femoropopliteal bypass that is routed through the femoral vein. […]

The post Endologix submits premarket approval application to FDA for Detour system appeared first on Vascular News.

Femoropopliteal bypass shows reintervention benefit over endovascular therapy for advanced premature PAD

Femoropopliteal bypass is associated with decreased reinterventions at one year compared to endovascular therapy in patients with advanced premature peripheral arterial disease (PAD). This is the primary conclusion of Tanner I Kim (Yale School of Medicine, New Haven, USA) and colleagues, writing in an article recently published online in the Journal of Vascular Surgery. The […]

The post Femoropopliteal bypass shows reintervention benefit over endovascular therapy for advanced premature PAD appeared first on Vascular News.